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ABSTRACT
Since its first description, the definition of 
Barrett's esophagus (BE) has evolved from the 
macroscopic visualization of gastric-appearing 
mucosa in the esophagus to the histologic 
identification of goblet cells confirming the 
presence of intestinal metaplasia within the 
esophagus. BE develops as a consequence of 
chronic mucosal injury in patients with long- 
lasting gastroesophageal reflux disease. The 
clinical significance of BE is that it is the only 
known risk factor for esophageal 
adenocarcinoma. Endoscopy and biopsy is 
necessary for the diagnosis of BE as well as for 
observing the development of dysplasia. The 
optimal treatment for Barrett's metaplasia and 
dysplasia is still being debated. Neither 
aggressive medical acid suppression nor 
antireflux surgery can induce a predictable 
regression of BE or exert a protective effect 
against its malignant degeneration. There is no 
consensus on a particular guideline for 
endoscopic surveillance with the means of 
repeating period and biopsy protocol. In the 
presence of low-grade dysplasia, endoscopic 
ablation modalities including multipolar 
electrocautery, argon plasma coagulation, 
endoscopic mucosal resection, heater probe, a 
variety of lasers, cryotherapy and photodynamic 
therapy should be subjected. Cancer can occur
under the re-epitheliazed mucosa following 
ablation. None of these approaches can obviate 
the need for continued endoscopic surveillance. 
Since patients with high-grade dysplasia are at 
high risk for having a focus of adenocarcinoma, 
esophagectomy should be indicated to those 
who are medically fit.
K e y  W o rd s :  Barrett's esophagus,
Gastroesophageal reflux, Endoscopy, Dysplasia, 
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IN T R O D U C T IO N
Norman Barrett (1) first described the columnar- 
lined esophagus in 1950 and he believed it to be 
associated with a congenital short esophagus. 
Although its etiology, pathophysiology, and 
malignant potential are much clearer today, 
controversies remain. The transition from normal 
squamous mucosa to columnar epithelium, 
named as Barrett's esophagus (BE), is almost 
always in response to chronic gastroesophageal 
reflux (2). It occurs in about one in 400 of the 
general population and about 15% of the patients 
with reflux esophagitis (3-5). Moreover, the 
autopsy prevalence of 376 cases per 100.000 is 
much higher than the clinical prevalence of 22.6
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cases per 100.000, and this shows that the 
majority of cases of BE in the general population 
are unrecognized. On the other hand, BE is the 
only identifiable premalignant condition for 
esophageal adenocarcinoma (6). The incidence 
of adenocarcinoma of the esophagus for these 
patients has been reported as 0.2-2.1% per year
(2). In other words, cancer has been estimated to 
develop in patients with BE at the rate of one 
case per 100-200 patient-years of follow-up, a 
30-125-fold increase in incidence over that in the 
general population (7,8). The original debate as 
to whether BE is congenital or acquired has 
shifted to a debate as to the exact cell of origin in 
the epithelium. Presence of goblet cells at the 
gastroesophageal junction identify BE and 
represents the earliest sign of BE (9). Although, 
there is some evidence for favoring surgical 
treatment rather than long-term acid suppression 
therapy, the facts need to be reviewed 
realistically with the current results of various 
clinical studies including medical therapy, 
antireflux surgery, and combined or sole 
endoscopic ablation modalities (10-20). The 
application of genetic markers is still deliberated 
and progressing (21). On the other hand, the 
need and details of surveillance programs to 
detect early cancer are also not resolved.
This article focuses on the controversies over 
diagnosis of high-grade dysplasia, recognizing 
early cancer, surveillance protocols and current 
therapeutic modalities as well as various 
endoscopic ablation methods, which promise 
satisfactory early results.
H is to p a th o lo g ic  D e f in it io n  o f  th e  
D is e a s e
Barrett's esophagus is usually diagnosed when 
an obvious segment of salmon pink columnar 
epithelium is seen to extend well above the 
gastroesophageal junction (9). The proximal 
junction of whitish squamous epithelium with pink 
columnar epithelium may be regular but is more 
commonly seen as presenting with flame-shaped 
extensions of the columnar epithelium (9). 
Histologic diagnosis is confirmed when three 
types of epithelium are found: a) gastric fundus- 
type epithelium lined by mucus-secreting cells, 
chief and parietal cells; b) gastric junctional-type 
epithelium with a foveolar surface and mucus- 
secreting cells; and c) specialized columnar
epithelium that has a villiform surface, mucus- 
secreting columnar cells, and goblet cells 
(intestinal metaplasia) (22). Ordinary epithelium 
is distinguished from specialized epithelium with 
the presence of goblet cells (9). It used to be 
accepted that at least 3 cm of macroscopic pink 
columnar epithelium seen at endoscopy was 
necessary for the diagnosis of BE. This 
hypothesis was based on the Hayward's 
statement that up to 2 cm segment could be seen 
in normal people (23). It has been shown that the 
short-segment columnar-lined esophagus could 
contain goblet cells and give rise to cancer (24) 
Segments shorter than 3 cm should be divided 
into two types, columnar epithelium with or 
without intestinal metaplasia. The presence of 
intestinal metaplasia varies with the extent of 
columnar epithelium lining the esophagus, and 
most long segments therefore have goblet cells
(25). BE is now defined as any length of 
columnar epithelium in the tubular esophagus 
with specialized intestinal metaplasia and has 
artificially been separated into long-segment (3 
cm or longer) and short-segment (less than 3 cm) 
disease (2). Small patches of gastric epithelium 
in the proximal esophagus can be seen in 2% to 
5% of endoscopic procedures (2). Esophageal 
adenocarcinoma is extremely rare in these inlet 
patches; they do not need to be biopsied or 
followed in surveillance programs.
P a th o g e n e s is
It is generally accepted that columnar 
replacement at the gastroesophageal junction is 
a repairing response to reflux trauma at that site, 
but the reason for the inclusion of goblet cells 
remains to be clarified (9). Premalignant potential 
possibly arises after a further stimulus by the 
addition of duodenal contents to the acid 
refluxate. Clinical evidence also supports the role 
of duodenal contents in the pathogenesis of 
dysplastic epithelium. However, the columnar 
lined epithelium that contains chief, parietal, and 
Paneth cells is not so simple and may secrete 5- 
hydroxytryptamine, somatostatin, gastrin, 
glucagon, motilin, pancreatic polypeptide, 
secretin, peptide tyrosine, and neurotensin (26). 
More recently, Shields et al. (27) and Sawhney et 
al. (28) have demonstrated and confirmed a 
distinctive cell type at the squamocolumnar 
junction in about one third of BE patients. It has 
been shown by electron microscopy that the cell
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is morphologic hybrid that shares features of both 
squamous and columnar cells (9). It may 
represent an intermediate step in the 
development of BE. If it is the basal cell in 
squamous esophageal epithelium, it could give 
rise to the distinctive cell and the development of 
BE. The finding of specialized intestinal 
metaplasia at a normal-appearing 
gastroesophageal junction is frequently 
associated with Helicobacter pylori infection (2). 
However, the fact that it is not associated with 
ethnic background or reflux symptoms, suggests 
that it is not clinically significant with respect to 
the development of esophageal 
adenocarcinoma. Similarly, columnar epithelium 
in the distal esophagus without specialized 
intestinal metaplasia is also not associated with 
ethnic background or reflux symptoms.
M o le c u la r  B asis  o f th e  D is e a s e
telomerase transcription (2). Recent data in 
biopsies from patients with early BE have shown 
both individual-and multiple-gene abnormalities 
in up to 50% of the cases (2,29,30). The genetic 
alterations appear to be equally distributed 
between cases with and without intestinal 
metaplasia. BE with intestinal metaplasia is 
mainly characterized by p53 gene mutation 
whereas there is a tumor suppressor gene allelic 
loss in patients with BE without intestinal 
metaplasia (2). These results suggest that a 
genetic instability due to the loss of 
heterozygosity of distinct oncosuppressor genes 
occurs first, while p53 gene mutations take place 
later and parallel to the morphological switch 
from nonintestinal to intestinal type of 
metaplasia. The clinical importance of intestinal 
metaplasia may be incorrect under these 
molecular biologic findings. Further studies 
concerning the molecular basis of the disease 
will bring light to the controversies.
Generally, carcinogenesis in metaplastic cells is 
thought to proceed through a series of genetic 
mutations that activate oncogenes and disable 
tumor suppressor genes. Adenocarcinoma 
arising on BE is characterized by a peculiar 
molecular profile that includes allelic loss of a 
number of tumor suppressor genes (p53, MTS1, 
APC, VHL, DPC4, Rb, DCC), p53 gene 
mutations, p16 gene promoter methylation, 
increased FHIT (fragile histidine triad) and
D ia g n o s is
The definitive diagnostic study for BE is 
endoscopy. Whereas other modalities such as 
radiology, scintigraphy, potential difference, 
manometry or pH studies may be suggestive, the 
diagnosis cannot be made without histologic 
proof (31).
Fig.l Current endoscopic surveillance in patients with Barrett's esophagus.
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Radiologic findings vary greatly, and the 
spectrum found in this disease ranges from 
stricture, hiatal hernia, free reflux, and/or 
esophageal ulceration to normal (32). There has 
been some interest in the reticular mucosal 
pattern as described by Levine et al, (33) but 
detection of such requires precise double­
contrast techniques and a trained eye. The 
sensitivity appears low, especially if seen in the 
absence of a stricture or hiatal hernia, because 
superficial carcinomas, varices, and drug- 
induced esophagitis may also give this 
appearance (34). However, as mentioned by 
Chernin et al (35) the presence and 
characteristics of a stricture have been the most 
important features leading to the diagnosis of BE. 
The diagnosis is strongly suggested by the 
findings of a complication occurring in the 
columnar epithelium. These complications are 
stricture, ulceration and carcinoma, especially in 
the patient with free reflux and hiatal hernia. It is 
important that the radiologist be aware of the 
implications of these findings and consider the 
diagnosis of BE. The 99mTc-pertechnetate test is 
of limited diagnostic value, because of its low 
sensitivity although it has a high specificity (36). 
The columnar lining of BE has been found to 
have a potential difference unlike that of the 
squamous lining of the esophagus, but it has little 
practical value due to its low sensitivity (37). It is 
not surprising that BE is associated with the 
characteristics of the extreme end of the 
spectrum of patients with an incompetent lower 
esophageal sphincter (LES) (38). The overall 
length, intra-abdominal length, and pressure 
profiles are all lower than in patients with other 
degrees of reflux (9). Similarly, results of pH 
studies show that the esophageal exposure to 
both acid and alkaline secretions falls at the 
extreme end of the spectrum in reflux disease 
(38). However, no data suggest that particular 
characteristics of the pH and motility studies 
have any diagnostic accuracy for BE. On the 
other hand, the endoscopic features of BE are 
well described. The level of mucosal change is 
measured with respect to the gastroesophageal 
junction, which is recognized by the proximal 
extent of the gastric folds (9, 39, 40). The 
columnar segment has been described using 
terms such as "salmon-pink-tongues" and "flame 
extensions" into the surrounding "pearly white” 
squamous epithelium (9). The suggestion of the 
endoscopic appearance of BE must prompt
multiple biopsies both to prove the diagnosis and 
to exclude the possibility of dysplasia or 
malignancy (9). Tytgat (41) suggested that four- 
quadrant biopsies must be taken every 2 cm of 
the columnar lining, whereas Nishimaki (42) 
stated that the area just above the 
endoscopically obvious columnar segment must 
always be biopsied carefully because it is a high- 
risk zone for dysplasia and malignancy. It has 
been known that severe dysplasia and 
adenocarcinoma may arise in segments of 
columnar lining of less than 3 cm (43). On the 
other hand, Clark et al (44) suggest performing 
routine retroflexed biopsies of the 
gastroesophageal junction from "below" in order 
not to miss a short-segment BE before a 
carcinoma develops.
Spectroscopic diagnosis of dyplasia in patient 
with BE has recently been advanced. 
Reflectance and fluorescence spectroscopy 
target chemical and structural features of 
biological tissue and the resulting spectra can 
provide quantitative diagnostic information (2). 
The short penetration depth of visible light makes 
these techniques well-suited for probing the 
epithelial linings of the body. Reflected light is the 
simplest spectroscopic technique. This strategy 
is based on the elastic scattering of white light, in 
which photons incident on the tissue are 
"scattered" back without change in wavelength. 
The targets for reflectance are tissue absorbers 
and scatterers. Hemoglobin is the most important 
tissue absorber. Mitochondria and cell nuclei are 
examples of important tissue scatterers. 
Reflected light thus contains morphological 
information about the tissue, such as data on the 
scattering and absorption properties of tissue, 
and the size distribution of the epithelial cell 
nuclei. Sites with high-grade dysplasia scatter 
light less than nondysplastic cells. The 
wavelength pattern of scattered light is 
dependent on the number and size of nuclei in 
the epithelial cell layer. This quantitative 
information is of direct interest because nuclear 
enlargement and crowding are key features used 
by pathologists to identify dysplasia. Wallace et 
al. (45) give the rate of sensitivity and specificity 
of this technique to distinguish dysplasia (low- 
and high - grade) from nondysplastic Barrett’s 
tissue as 92% and 97%, respectively. 
Fluorescence is the most widely-used spectral 
diagnostic technique. Fluorescence spectra in
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biological tissue contain distortions due to the 
interplay with scattering and absorption in the 
tissue. Spectroscopic signals can provide the 
same type of information as histochemistry 
and histopathology, but without the removal of 
tissue.
T re a tm e n t
Management of BE is controversial. There are 
two different modalities: 1) medical therapy with 
proton pump inhibitors (PPI) and prokinetics, and
2) minimally invasive laparoscopic techniques to 
repair the defective LES (9). PPI reduce the 
gastric output and also the volume of the 
refluxate, but some reflux of both acid and 
duodenal content may continue. It is not exactly 
known whether this reduction will prevent 
complications. It has been shown that elevation 
of the head of the bed, decreased fat intake, 
cessation of smoking, and avoiding recumbency 
for 3 hours postprandially diminish reflux 
episodes. PPI gives better results than H2 
receptor antagonists in the medical management 
of reflux esophagitis (46). However, it has been 
shown that after 12 months of therapy with 
lansoprazole, 30 mg daily, one third of patients 
were still symptomatic, and only 52% of grade III 
and IV esophagitis remained healed (47). 
Omeprazole and lansoprazole gave similar 
healing rates, which were excellent for grade I 
and II esophagitis and less effective for more 
severe esophagitis. On the other hand, Kuipers 
et al. (48) reported that patients with reflux 
esophagitis and Helicobacter pylori infection who 
were treated with omeprazole were at an 
increased risk for developing atrophic gastritis. 
The patients having similar status who were 
treated by fundoplication did not develop atrophic 
gastritis. Therefore, it can be suggested that it is 
important to eradicate Helicobacter pylori 
infection if omeprazole therapy is used to treat 
patients with reflux esophagitis.
The surgical treatment of BE can be summarized 
as antireflux surgery and esophagectomy. 
Antireflux surgery is used to restore LES function 
and to abolish reflux of gastric and duodenal 
contents into the esophagus. Although the 
Nissen fundoplication is the most widely-used 
procedure, the choice of the surgical approach 
varies with the surgeon's preference as well as 
according to the status of the esophageal
peristaltis and the pressure in the body of the 
esophagus (9). If the mean pressure in the body 
of the esophagus is less than 25 mmHg and the 
patient has lost peristaltis, a full 360-degree 
fundoplication should be avoided (49). In such 
cases a partial fundoplication is preferred. 
However, partial fundoplication such as Toupet, 
Belsey-Mark IV, Watson or Dor procedures, may 
not control all reflux and the long-term results of 
follow-up may not be as good as in the case of 
the Nissen fundoplication (9). In the case of 
mean pressure in the esophageal body greater 
than 25 mmHg with normal peristaltis, the 
esophagus is effectively cleared of a swalloved 
bolus (50). Antireflux surgery can be performed 
either with open or laparoscopic procedure, but 
the latter is most commonly preferred. The 
results of laparoscopic Nissen fundoplication 
have been excellent with a mortality rate of less 
than 0.1% and a morbidity rate ranging from 6% 
to 25% (51). This is the most important point that 
laparoscopic fundoplication should be performed 
identically to the open technique. In other words, 
the crura should be approximated and a floppy 
Nissen performed over an adequate size of 
bougie (52). The taking down of short gastric 
vessels depends on the surgeon's preference 
even though it is most widely performed. On the 
other hand, if the patient has a shortened 
esophagus, which seldom occurs, besides a 
hiatal hernia greater than 5 cm and stricture and 
narrowing, the alternative transthoracic Collis 
lengthening and antireflux procedure such as 
Belsey-Mark IV should be considered (9).
Esophagectomy is performed in patients which 
have BE and high-grade dysplasia or 
adenocarcinoma of the esophagus developed on 
BE. The decision to operate for high-grade 
dysplasia should be based on balancing the risk 
of overlooking and adenocarcinoma against the 
hazards of surgery. The overall mortality rate of 
esophagectomy for high-grade dysplasia has 
been reported as 0-14% (53-55).
Esophagectomy carries some early and late 
complications. Esophagectomy can be 
performed either with laparotomy and transhiatal 
resection with cervical anastomosis or complete 
laparoscopic or combined laparoscopic and 
thoracoscopic resection with cervical 
anastomosis, which is called minimally invasive 
esophagectomy. Nguyen et al. (56) advise the 
latter technique for its feasibility and safety.
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Zaninotto et al. (57) performed esophageal 
resection in patients with high-grade dysplasia 
and BE and found that these patients had a 33% 
probability of harboring invasive esophageal 
carcinoma but even a second endoscopy failed 
to identify patients with invasive tumor. They 
gave good results of esophagectomy without any 
mortality in their series.
Despite recent advances in surgical and 
multidisciplinary treatment, the prognosis for 
patients with adenocarcinoma of BE remains 
poor. Bottger et al. (58) studied tumor DNA 
ploidy, an additional parameter to pathologic 
TNM staging, to determine the prognosis of the 
patients who underwent transhiatal or
transthoracic esophageal resection due to 
adenocarcinoma of BE. They found that patients 
with a diploid or tetraploid tumor without distant 
metastasis and a tumor stage pT1-pT3 had 
curative (RO) resection, whereas in the case of 
an aneuploid DNA content or a pT4 tumor 
resection alone showed no advantage as 
compared to palliative nonoperative procedures. 
These data are contradictory to the conclusion of 
Zaninotto et al. (57) that molecular biology 
markers cannot improve diagnostic accuracy.
Endoscopic S u rv e il la n c e  lo r  BE
During the last 10 years, numerous endoscopic 
surveillance algorithms have been suggested 
and used. The recommendations made by the 
Barrett's Esophagus Working Party in 1991 are 
not followed, possibly because they are not 
practical (59). The most popularized algorithm in 
current practice, formed by Stein (60) in 1996, is 
shown in Fig. 1. Using a strict biopsy protocol is 
helpful for differentiating high-grade dysplasia 
from carcinoma, but contradictory results about 
this type of rigorous biopsy protocol have been 
published (61). Most groups propose four biopsy 
specimens, in a circular fashion, from every 2 cm 
of the Barrett's epithelium, with additional 
biopsies from any mucosal abnormality. De 
Looze (61) suggests a four quadrant biopsies at 
1 cm interval in patients who have low-grade 
dysplasia if numerous biopsies reveal dysplasia 
to detect foci of high-grade dysplasia or cancer. 
Morales and Sampliner (62) recommend 
endoscopic surveillance every 3 years for 
patients who do not develop dysplasia, every 6 
months for patients with low-grade dysplasia
over the next year, then at 1-year intervals if 
there has not been progression to high-grade 
dysplasia. They also suggest that, when a high- 
grade dysplasia is shown, the patients should 
undergo surgical resection, if they are medically 
fit for this procedure.
On the other hand, postoperative morbidity after 
correction of esophageal atresia is partly 
determined by gastroesophageal reflux disease, 
which has been proven to affect from one-half to 
two-thirds of the patients during childhood. Krug 
et al. (63) showed that the incidence of reflux 
symptoms, reflux esophagitis, and BE were 
significantly higher than in the normal population. 
They concluded that this group seems to be at 
risk for developing BE and advised endoscopy in 
all patients at adulthood.
In a recent study, aimed at determining the 
current practices that clinicians employ in the 
management of BE in the UK, it was shown that 
the majority (70%) performed surveillance 
despite the absence of a controlled trial showing 
a benefit for screening (7). In the group that did 
not carry out screening in this study, the most 
commonly cited reason was lack of evidence 
showing benefit. Similarly, the results of another 
trial about surveillance of BE in the Netherlands 
showed that most of the questionnaire 
respondents (84%) performed regular 
endoscopic follow-up of BE (64). But there Is 
limited uniformity in the frequency and intensity of 
endoscopic histological follow-up resulting from 
conflicting data and recommendation in the 
literature. These facts indicate that an updated 
consensus is needed in this area.
A b la t io n  th e r a p y
The efforts to ablate the Barrett's mucosa with 
either chemical, thermal, or ultrasonic energy 
have given best results hoping that normal 
squamous epithelium will replace the Barrett's 
lining and its malignant potential (65). However, 
the clinical value of endoscopic ablation is 
controversial. Major concerns of these methods 
are the persistence of residual metaplastic 
glands beneath the new squamous epithelium 
and the absence of any knowledge of its impact 
on long-term outcome. Van Laetham et al. (66) 
recently reported a case of an intramucosal 
adenocarcinoma diagnosed 18 months after
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apparently complete squamous reeplthellzatlon 
achieved using argon plasma coagulation and 
high dose omeprazole. Moreover, the patient 
initially had Barrett's esophagus without 
dysplasia. Similarly Bonavina et al. (15) reported 
a case with an adenocarcinoma undermining 
regenerated squamous epithelium, 6 months 
after eradication by endoscopic laser ablation. 
These reports show the fact that the residual 
glands might still be premalignant and that the 
early diagnosis of neoplastic changes might be 
compromised by the squamous re-epithelization. 
This finding also stresses that the histological 
proof of malignancy need not be established 
before esophagectomy is proposed 
controversially to some authors' beliefs (61). 
Although patients with high-grade dysplasia and 
intramucosal adenocarcinoma on biopsy who do 
not have an endoscopically visible lesion are 
unlikely to have lymphatic métastasés, 7% do 
have submucosal invasion. Thus, even in these 
very early tumors, treatment directed only at the 
mucosa may be inadequate (67).
Photodynamic therapy (PDT) is a treatment 
modality that utilizes a photosensitizing drug 
activated by laser-generated light (13). PDT 
might establish itself as a minimally invasive 
treatment alternative compared with surgery for 
high-grade dysplasia or early mucosal cancer of 
the esophagus.
Argon plasma coagulation (APC) has been used 
with a curative aim for the destruction of high- 
grade dysplasia in BE and early esophageal 
cancer. May et al. (14) suggest that APC might 
offer an effective, minimally invasive alternative 
to mucosectomy or photodynamic therapy, as the 
treatment procedure is less cumbersome and the 
equipment less expensive. The early results of 
argon plasma coagulation for the eradication of 
BE in the short-term are very attractive, but long­
term follow-up of treated patients seems 
mandatory before drawing definitive conclusions 
about this therapy (10,12,14,18).
Endoscop ic M u c o s a l R e s e c tio n
In view of the mortality and morbidity rates of 
esophagectomy and the relatively large group of 
inoperable patients, local therapeutic techniques 
are required for high-grade dysplasia and early
Barrett’s cancer. Endoscopic mucosal resection 
of early carcinoma in BE is associated with 
promisingly low morbidity and mortality rates
(11). This procedure may offer a new minimally 
invasive therapeutic alternative to 
esophagectomy, especially in low-risk situations.
In conclusions, since the development of 
Barrett’s adenocarcinoma follows a multistep 
process from metaplasia through increasingly 
severe grades of dysplasia, close endoscopic 
surveillance with extensive biopsies currently 
remains the only means to identify patients at risk 
for malignant degeneration and detect 
esophageal adenocarcinoma at an early and 
curable stage. Moreover, columnar epithelium 
has been found underlying the regenerated 
squamous epithelium, suggesting that life-long 
surveillance is warranted. Several therapeutic 
modalities either medically or surgically give 
promising short-term results, but not satisfactory 
in all the patients. Although during the last 
decade of the second millennium, many changes 
including definition, pathogenesis, diagnostic 
approaches, and therapeutic modalities of 
Barrett’s esophagus have been observed, it 
seems that the searches will be continued in this 
area at least in the early 2000’s.
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